Pelthos Therapeutics Inc. (NASDAQ: PTHS) Director Peter Greenleaf executed a series of stock sales totaling $20,826 on July 2, 2026. The transactions, facilitated through a Rule 10b5-1 plan established in December 2025, were designated to cover tax liabilities associated with vesting restricted stock units. Following the divestment, Greenleaf retains direct ownership of 23,884 shares. This activity occurs against a backdrop of a 14% stock price decline over the preceding week, with PTHS trading at $24.60. The sale coincides with the company's recent announcement of a substantial earnings per share miss for the first quarter of 2026, alongside notable index inclusions and a significant purchase by another director.
The divestment consisted of two separate blocks of equity. Greenleaf liquidated 712 shares at a weighted average price of $25.9954 per share. These specific trades were executed within a price band of $25.58 to $26.53. Concurrently, an additional 85 shares were sold at a weighted average price of $27.2733 per share. The execution prices for this second tranche ranged from $27.20 to $27.63. The cumulative value of all 797 shares sold reached $20,826. The entire transaction sequence was governed by the pre-arranged Rule 10b5-1 plan, which was formally adopted on December 16, 2025. The explicit purpose outlined for these transactions was to satisfy estimated tax obligations linked to the vesting of restricted stock units granted by Pelthos Therapeutics Inc.
Following the completion of these direct ownership transactions, Peter Greenleaf's direct holdings in Pelthos Therapeutics Inc. common stock stand at 23,884 shares. The timing of this insider sale is notable given the recent price action for PTHS. The stock has experienced a decline of approximately 14% over the past week. At the time of reporting, the shares were trading at $24.60, a level that sits below the prices at which Greenleaf executed his sales. Market analysis suggests that the stock may currently be undervalued relative to historical peaks. Specifically, shares are trading 55% below their 52-week high of $54.29. Investors seeking deeper insights can access comprehensive analysis and Fair Value estimates for PTHS through InvestingPro’s detailed Pro Research Report.
Broader corporate developments at Pelthos Therapeutics Inc. include the reporting of first-quarter 2026 earnings, which revealed a significant shortfall in earnings per share (EPS) expectations. The company posted an actual EPS of -3.09 USD, missing the forecasted -0.51 USD. This discrepancy resulted in a surprise of -505.88%. Despite this earnings miss, the company has shown strong revenue growth and product performance, which may have contributed to investor confidence. Additionally, Pelthos Therapeutics has been added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark Indexes as part of the 2026 Russell indexes reconstitution. This inclusion, effective June 29, ranks the company among the 4,000 largest U.S. stocks by total market capitalization. In another development, a significant stock purchase was made by director Todd C. Davis, who acquired 35,948 shares for approximately $999,980. These recent developments highlight the company’s ongoing activities and market presence.